Talus Bio’s Post

View organization page for Talus Bio, graphic

3,068 followers

"I like to think of [proteomics] not as a big data science approach, but as the technology of choice to perform mechanistic biological studies – a next-level version of cell biology and biochemistry with a larger scale and broader scope." - Oliver Rinner, CEO of Biognosys The leaders of Biognosys and Bruker recently shared their perspectives on how mass spectrometry and proteomics are leading the charge in drug development, helping biologists understand cell biology much faster and more efficiently than ever before. We're thrilled to see industry leaders exploring how to utilize mass spectrometry to understand protein function in context and at scale to accelerate therapeutic development. https://lnkd.in/ei_jazqC #TeamMassSpec #chemoproteomics

Mass spectrometry and proteomics: leading the charge in drug development

Mass spectrometry and proteomics: leading the charge in drug development

iptonline.com

To view or add a comment, sign in

Explore topics